Cancer 116:2884–2889īoughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. J Clin Oncol 30:1796–1804ĭominici LS, Negron Gonzalez VM, Buzdar AU et al (2010) Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Von Minckwitz G, Untch M, Blohmer J-U et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Hennessy BT, Hortobagyi GN, Rouzier R et al (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. Gralow JR, Burstein HJ, Wood W et al (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
#Pcr complete response trial#
Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. When residual enhancement on MRI is subtle and seen only in the delayed phase, this finding could be associated with false-negative pCR results.In patients with breast cancer after completion of neoadjuvant chemotherapy, the diagnostic accuracy of MRI for predicting pathologic complete response (pCR) differed according to molecular subtype.When the residual enhancement on MRI after NAC is subtle and seen only in the delayed phase, overinterpretation of residual tumors should be performed with caution. The diagnostic accuracy of MRI for predicting pCR differed by molecular subtypes. The subtle residual enhancement observed only in the delayed phase was associated with false-negative findings (76.2%, p = 0.016). MRI in the HR − /HER2 + type showed the highest false-negative rate (18.81%) for predicting pCR. The overall accuracy for predicting pCR using MRI was 76.68%. Pearson’s χ 2 and Wilcoxon rank-sum tests were used for MRI findings causing false-negative pCR. Residual lesions on post-NAC MRI were divided into overt and subtle which classified as nodularity or delayed enhancement. Tumors were divided according to hormone receptor (HR) and human epidermal growth factor receptor (HER) 2. pCR was determined based on the final pathology reports. The diagnostic performance of MRI predicting pCR was evaluated. Two breast radiologists dichotomized the post-NAC MRI findings as radiologic complete response (rCR) and no-rCR. MethodsĪ total of 506 patients with breast cancer who underwent MRI after NAC and underwent surgery between January and December 2018 were included. This study aimed to investigate the predictability of breast MRI for pathologic complete response (pCR) by molecular subtype in patients with breast cancer receiving neoadjuvant chemotherapy (NAC) and investigate the MRI findings that can mimic residual malignancy.
0 kommentar(er)
